Quick Answer
Twist Bioscience Corp reported Net Income Loss of -$77.67 million for the year ending 2025.
- Twist Bioscience Corp showed an increase of +62.8% in Net Income Loss from 2024 to 2025.
- This data is from Twist Bioscience Corp's annual report (Form 10-K), filed with the SEC on November 17, 2025.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2017: -$16.94 million | Q1 2018: -$16.87 million | Q2 2018: -$17.62 million | Q4 2018: -$22.64 million | Q1 2019: -$25.93 million | Q2 2019: -$27.92 million | Q4 2019: -$55.64 million | Q1 2020: -$31.77 million | Q2 2020: -$28.21 million | Q4 2020: -$32.90 million | Q1 2021: -$37.92 million | Q2 2021: -$40.04 million | Q4 2021: -$45.56 million | Q1 2022: -$60.67 million | Q2 2022: -$60.52 million | Q4 2022: -$41.82 million | Q1 2023: -$59.16 million | Q2 2023: -$57.40 million | Q4 2023: -$43.01 million | Q1 2024: -$45.49 million | Q2 2024: -$85.57 million | Q4 2024: -$31.59 million | Q1 2025: -$39.33 million | Q2 2025: $20.39 million | Q4 2025: -$30.51 million.
- Over the full 9 years of available data (2017 to 2025), Twist Bioscience Corp's Net Income Loss has declined by 31.0%.
- Historical annual values: Fiscal year 2025: -$77.67 million | Fiscal year 2024: -$208.73 million | Fiscal year 2023: -$204.62 million | Fiscal year 2022: -$217.86 million | Fiscal year 2021: -$152.10 million | Fiscal year 2020: -$139.93 million | Fiscal year 2019: -$107.67 million | Fiscal year 2018: -$71.24 million | Fiscal year 2017: -$59.31 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: